Table 1.
Characteristic | Categories | Data |
---|---|---|
Age | Median (min–max), years | 65 (28–77) |
Time since first chemotherapy for metastatic colorectal cancer | Median (min–max), years | 1.8 (0.4–10.9) |
n | ||
Sex | Female | 47 |
Male | 53 | |
Localization of primary tumor | Right colon | 30 |
Left colon | 31 | |
Rectum | 35 | |
NR | 4 | |
No of metastatic sites | 1–2 | 54 |
2+ | 46 | |
Performance status | 0 | 43 |
1 | 54 | |
NR | 3 | |
Treatment, adjuvant | Fluoropyrimidine monotherapy | 36 |
Fluoropyrimidine and oxaliplatin | 30 | |
Treatment, metastatic | Fluoropyrimidine | 96 |
Oxaliplatin | 87 | |
Irinotecan | 98 | |
Bevacizumab | 90 | |
EGFR inhibitor | 33 | |
Other | 5 | |
NR | 2 | |
Mutation in tumor tissue | KRAS | 51 |
NRAS | 4 | |
BRAF | 6 | |
Wild-type or NR | 39 |